Skip to main content

Table 2 Genotype frequencies of the study and control group with the risk analysis’ results

From: Genetic variability of inflammation and oxidative stress genes does not play a major role in the occurrence of adverse events of dopaminergic treatment in Parkinson’s disease

Gene

Genotype

N (%) in the study group

N (%) in the control group

OR (95%CI)

p value

OR**

(95%CI**)

p value**

NLRP3 rs35829419

CC

196 (87.5)

120 (82.2)

 

CA

27 (12.1)

22 (15.1)

AA

1 (0.4)

4 (2.7)

CARD8 rs2043211

AA

105 (46.9)

66 (45.2)

Ref.

 

Ref.

 

AT

89 (39.7)

64 (43.8)

0.87 (0.56–1.36)

0.553

0.85 (0.53–1.38)

0.515

TT

30 (13.4)

16 (11.0)

1.18 (0.60–2.33)

0.636

1.48 (0.72–3.04)

0.290

AT+TT

119 (53.1)

80 (54.8)

0.94 (0.62–1.42)

0.753

0.97 (0.62–1.52)

0.893

IL1β* rs16944

AA

25 (11.2)

21 (14.4)

0.64 (0.33–1.24)

0.183

0.76 (0.37–1.55)

0.447

AG

89 (39.7)

66 (45.2)

0.72 (0.46–1.13)

0.157

0.72 (0.45–1.16)

0.176

GG

110 (49.1)

59 (40.4)

Ref.

 

Ref.

 

AA+AG

114 (50.9)

87 (59.6)

0.70 (0.46–1.07)

0.101

0.73 (0.46–1.14)

0.166

IL1β rs1143623

GG

131 (58.5)

67 (45.9)

Ref.

 

Ref.

 

GC

79 (35.3)

64 (43.8)

0.63 (0.41–0.98)

0.041

0.62 (0.38–0.99)

0.043

CC

14 (6.3)

15 (10.3)

0.48 (0.22–1.05)

0.065

0.47 (0.20–1.11)

0.084

GC+CC

93 (41.6)

79 (54.1)

0.60 (0.40–0.92)

0.018

0.59 (0.38–0.92)

0.021

TNF-α rs1800629

GG

156 (69.6)

99 (67.8)

Ref.

 

Ref.

 

GA

59 (26.3)

42 (28.8)

0.89 (0.56–1.43)

0.631

0.88 (0.53–1.46)

0.629

AA

9 (4.0)

5 (3.4)

1.14 (0.37–3.51)

0.816

1.51 (0.47–4.83)

0.487

GA+AA

68 (30.3)

47 (32.2)

0.92 (0.59–1.44)

0.709

0.95 (0.59–1.53)

0.824

IL6 rs1800795

GG

65 (29.0)

45 (30.8)

Ref.

 

Ref.

 

GC

120 (53.6)

67 (45.9)

1.24 (0.77–2.01)

0.383

1.04 (0.62–1.74)

0.885

CC

39 (17.4)

34 (23.3)

0.79 (0.44–1.44)

0.449

0.72 (0.38–1.36)

0.312

GC+CC

159 (71.0)

101 (69.2)

1.09 (0.69–1.72)

0.711

0.93 (0.57–1.52)

0.782

NOS1 rs2293054

GG

118 (52.7)

87 (59.6)

 

GA

89 (48.2)

43 (29.5)

AA

17 (7.6)

16 (11.0)

NOS1 rs2682826

GG

108 (48.2)

73 (50.0)

Ref.

 

Ref.

 

GA

101 (45.1)

57 (39.0)

1.20 (0.77–1.86)

0.422

1.16 (0.72–1.85)

0.548

AA

15 (6.7)

16 (11.0)

0.63 (0.30–1.36)

0.242

0.64 (0.28–1.44)

0.279

GA+AA

116 (51.8)

73 (50.0)

1.07 (0.71–1.63)

0.737

1.04 (0.67–1.63)

0.857

GPX1 rs1050450

CC

115 (51.3)

71 (49.0)

Ref.

 

Ref.

 

CT

92 (41.1)

60 (41.4)

0.95 (0.61–1.47)

0.807

0.97 (0.61–1.56)

0.908

TT

17 (7.6)

14 (9.7)

0.75 (0.35–1.61)

0.461

0.69 (0.30–1.56)

0.371

CT+TT

109 (48.7)

74 (51.1)

0.92 (0.61–1.40)

0.703

0.93 (0.59–1.45)

0.738

CAT rs10836235

CC

172 (76.8)

117 (80.1)

Ref.

 

Ref.

 

CT

47 (21.0)

25 (17.1)

1.28 (0.75–2.19)

0.371

1.34 (0.76–2.38)

0.311

TT

5 (2.2)

4 (2.7)

0.85 (0.22–3.23)

0.812

0.65 (0.15–2.72)

0.552

CT+TT

52 (23.2)

29 (19.8)

1.22 (0.73–2.03)

0.446

1.24 (0.72–2.13)

0.438

CAT rs1001179

GG

122 (54.5)

89 (61.4)

Ref.

 

Ref.

 

GA

92 (41.1)

51 (35.2)

1.32 (0.85–2.04)

0.219

1.01 (0.63–1.62)

0.974

AA

10 (4.5)

5 (3.4)

1.46 (0.48–4.42)

0.504

1.77 (0.54–5.79)

0.348

GA+AA

102 (45.6)

56 (38.6)

1.34 (0.88–2.06)

0.173

1.08 (0.68–1.70)

0.757

SOD2 rs4880

CC

65 (29.0)

40 (27.4)

Ref.

 

Ref.

 

CT

108 (48.2)

69 (47.3)

0.96 (0.59–1.58)

0.882

0.95 (0.56–1.62)

0.861

TT

51 (22.8)

37 (25.3)

0.85 (0.48–1.51)

0.577

0.74 (0.39–1.37)

0.335

CT+TT

159 (71.0)

106 (72.6)

0.92 (0.58–1.47)

0.735

0.88 (0.53–1.45)

0.605

  1. Alleles are provided as constructed by the manufacturer. The ancestral allele is matched with the dbSNP
  2. *Recessive model was used
  3. **Adjusted for sex and age
  4. Nominally significant results are written in bold text
Back to article page

Journal of Neuroinflammation

ISSN: 1742-2094